OptiBiotix Health PLC Appointment of Sales and Marketing Director (4011U)

TIDMOPTI

RNS Number : 4011U

OptiBiotix Health PLC

18 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Sales and Marketing Director

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Christina Wood as Sales and Marketing Director. Christina will join the OptiBiotix Board subject to completion of the normal regulatory due diligence.

Christina has over 20 years' sales experience within the food, nutrition, and nutraceuticals industry. As the owner and CEO of Confoco, a supplier of high quality food ingredients worldwide, Christina grew the business from GBP1m to GBP10m sales by obtaining strategic supplier status with multiple global corporates including Nestlé, Danone, and Heinz. During this time, she developed a network of agents and distributors across key international markets. Christina sold her company to Diana Naturals in 2013 which was subsequently acquired by Symrise AG for US$1.75 billion in 2014. She joined John Morley, a leading food industry supplier, in late 2014 where as Director of Sales and Marketing, she was responsible for key consumer accounts including Sainsbury's, Waitrose, M&S and Tesco.

She has been a finalist for Director of the Year for 'SME and International Trade' on two occasions and has been awarded the Nutricia Partners in Growth Award. Christina is fluent in German and Spanish.

Christina has extensive experience in building and managing supply chain agreements across international markets with leading industry players, and has both business to business, and business to retail sales experience. Her sales and marketing experience within the food, nutrition, and nutraceuticals industry and network of global contacts will help grow revenues of OptiBiotix's products across multiple application areas and international markets.

Stephen O'Hara, CEO of OptiBiotix, commented: "Christina's experience of building sales in her own business by developing relationships with food ingredient manufacturers and major retailers brings new elements of operational, commercial and industry expertise to OptiBiotix. Her skills in building and managing international networks of agents and distributors will be invaluable in taking OptiBiotix's patented SlimBiome(R) technology for hunger free weight loss and its LP-LDL(R) probiotic strain for cholesterol and hypertension reduction into overseas markets. This will help create multiple revenue streams from OptiBiotix's growing pipeline of products."

For further information, please contact:

 
 OptiBiotix Health plc                                www.optibiotix.com 
 Stephen O'Hara, Chief Executive                             Contact via 
                                                          Walbrook below 
 
 Cairn Financial Advisers LLP (NOMAD)                      Tel: [phone] 
                                                                    0883 
 Liam Murray 
 
   finnCap (Broker)                                        Tel: [phone] 
                                                                    0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                                   Tel: [phone] or 
                                               [e-mail] 
 Anna Dunphy                                                Mob: 07876 
                                                               741 001 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABRMFTMBABBBR

(END) Dow Jones Newswires

January 18, 2017 02:00 ET (07:00 GMT)